Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.55 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GFER | P55789 | 2/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165614 | 0.89 | GAA (0.67) | ADORA1ALOX5GAAALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5167299 | 0.88 | GAA (0.65) | ADORA1ALOX5GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL5168292 | 0.88 | PABPC1 (0.66) | ADORA1ALOX5GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL5166636 | 0.84 | GAA (0.69) | ADORA1ALOX5GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL15152565 | 0.84 | ALOX5 (0.49) | ADORA1ALOX5GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL7083359 | 0.84 | ALOX5 (0.48) | ADORA1ALOX5GAAALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5169512 | 0.83 | ALOX5 (0.47) | ADORA1ALOX5GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL7083935 | 0.83 | ALOX5 (0.49) | ADORA1ALOX5GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL5165259 | 0.83 | PRKAB2 (0.47) | ADORA1ALOX5GAAALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5166124 | 0.82 | ALOX5 (0.48) | ADORA1ALOX5GAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| EP-1326613-B2 | USE OF SUBSTITUTED IMIDAZO 1,2-A|PYRIDINE-, IMIDAZO ¬1,2-A|PYRIMIDINE AND IMIDAZO ¬1,2-A|PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1326613-B1 | USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO [1,2-A]PYRIMIDINE AND IMIDAZO [1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023972-A1 | Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS | NOS1, PTGIS, NOS2 | ADORA1 186/4885ALOX5 115/4885GAA 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.